Medicinal Product Regulation: Portugal׳s Framework.

Detalhes bibliográficos
Autor(a) principal: Herdeiro, Maria Teresa
Data de Publicação: 2016
Outros Autores: Bastos, PD, Rodrigues, A, Roque, Fátima
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10314/3093
Resumo: PURPOSE: The pharmaceutical industry is one of the most tightly regulated sectors, and it is essential to know each country׳s legal framework to understand the regulation, approval, and marketing of medicinal products for human use. This article describes the main statutes and procedures governing medicinal products for human use in Portugal and the role of the country׳s National Medicines and Health Products Authority (Autoridade Nacional do Medicamento e Produtos de Saúde, I.P.; INFARMED). METHODS: From the most recently available data, an update of requests and approvals concerning marketing authorizations, variations, pricing, and reimbursements is provided. Data were sourced from the INFARMED website, Infomed (database of medicinal products for human use), and periodic reports issued by national authorities. Organic laws, acts, and law decrees published in the government gazette (Diário da República) are cited and reproduced as required. FINDINGS: In 2015 Portugal ranked fifth in the European System of Medicines Evaluation in terms of the number of completed procedures as a reference member state. Approximately 80% of all approved drug applications in Portugal in 2015 were for generic drugs, mostly pertaining to the nervous system. In Portugal, INFARMED monitors drug quality, safety profile, and efficacy in all stages of the drug life cycle, ensuring patients' safety. IMPLICATIONS: The Portuguese market for medicinal products for human use has been appreciably changed by the advent of generic drugs. There is an increased trend for new request applications for biological and biotechnological substances.
id RCAP_804fed685bf8abac2b609b061ddd5e1d
oai_identifier_str oai:bdigital.ipg.pt:10314/3093
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Medicinal Product Regulation: Portugal׳s Framework.National RegulatoryAgencyPortugalMarketing authorizationmedicinal products regulationPURPOSE: The pharmaceutical industry is one of the most tightly regulated sectors, and it is essential to know each country׳s legal framework to understand the regulation, approval, and marketing of medicinal products for human use. This article describes the main statutes and procedures governing medicinal products for human use in Portugal and the role of the country׳s National Medicines and Health Products Authority (Autoridade Nacional do Medicamento e Produtos de Saúde, I.P.; INFARMED). METHODS: From the most recently available data, an update of requests and approvals concerning marketing authorizations, variations, pricing, and reimbursements is provided. Data were sourced from the INFARMED website, Infomed (database of medicinal products for human use), and periodic reports issued by national authorities. Organic laws, acts, and law decrees published in the government gazette (Diário da República) are cited and reproduced as required. FINDINGS: In 2015 Portugal ranked fifth in the European System of Medicines Evaluation in terms of the number of completed procedures as a reference member state. Approximately 80% of all approved drug applications in Portugal in 2015 were for generic drugs, mostly pertaining to the nervous system. In Portugal, INFARMED monitors drug quality, safety profile, and efficacy in all stages of the drug life cycle, ensuring patients' safety. IMPLICATIONS: The Portuguese market for medicinal products for human use has been appreciably changed by the advent of generic drugs. There is an increased trend for new request applications for biological and biotechnological substances.Clinical Therapeutics2016-11-11T17:22:58Z2016-11-112016-08-27T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttp://hdl.handle.net/10314/3093http://hdl.handle.net/10314/3093engdoi: 10.1016/j.clinthera.2016.07.171Herdeiro, Maria TeresaBastos, PDRodrigues, ARoque, Fátimainfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-01-14T02:56:22Zoai:bdigital.ipg.pt:10314/3093Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T01:42:30.794683Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Medicinal Product Regulation: Portugal׳s Framework.
title Medicinal Product Regulation: Portugal׳s Framework.
spellingShingle Medicinal Product Regulation: Portugal׳s Framework.
Herdeiro, Maria Teresa
National RegulatoryAgency
Portugal
Marketing authorization
medicinal products regulation
title_short Medicinal Product Regulation: Portugal׳s Framework.
title_full Medicinal Product Regulation: Portugal׳s Framework.
title_fullStr Medicinal Product Regulation: Portugal׳s Framework.
title_full_unstemmed Medicinal Product Regulation: Portugal׳s Framework.
title_sort Medicinal Product Regulation: Portugal׳s Framework.
author Herdeiro, Maria Teresa
author_facet Herdeiro, Maria Teresa
Bastos, PD
Rodrigues, A
Roque, Fátima
author_role author
author2 Bastos, PD
Rodrigues, A
Roque, Fátima
author2_role author
author
author
dc.contributor.author.fl_str_mv Herdeiro, Maria Teresa
Bastos, PD
Rodrigues, A
Roque, Fátima
dc.subject.por.fl_str_mv National RegulatoryAgency
Portugal
Marketing authorization
medicinal products regulation
topic National RegulatoryAgency
Portugal
Marketing authorization
medicinal products regulation
description PURPOSE: The pharmaceutical industry is one of the most tightly regulated sectors, and it is essential to know each country׳s legal framework to understand the regulation, approval, and marketing of medicinal products for human use. This article describes the main statutes and procedures governing medicinal products for human use in Portugal and the role of the country׳s National Medicines and Health Products Authority (Autoridade Nacional do Medicamento e Produtos de Saúde, I.P.; INFARMED). METHODS: From the most recently available data, an update of requests and approvals concerning marketing authorizations, variations, pricing, and reimbursements is provided. Data were sourced from the INFARMED website, Infomed (database of medicinal products for human use), and periodic reports issued by national authorities. Organic laws, acts, and law decrees published in the government gazette (Diário da República) are cited and reproduced as required. FINDINGS: In 2015 Portugal ranked fifth in the European System of Medicines Evaluation in terms of the number of completed procedures as a reference member state. Approximately 80% of all approved drug applications in Portugal in 2015 were for generic drugs, mostly pertaining to the nervous system. In Portugal, INFARMED monitors drug quality, safety profile, and efficacy in all stages of the drug life cycle, ensuring patients' safety. IMPLICATIONS: The Portuguese market for medicinal products for human use has been appreciably changed by the advent of generic drugs. There is an increased trend for new request applications for biological and biotechnological substances.
publishDate 2016
dc.date.none.fl_str_mv 2016-11-11T17:22:58Z
2016-11-11
2016-08-27T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10314/3093
http://hdl.handle.net/10314/3093
url http://hdl.handle.net/10314/3093
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv doi: 10.1016/j.clinthera.2016.07.171
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Clinical Therapeutics
publisher.none.fl_str_mv Clinical Therapeutics
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799136918417440768